IMPLANON Drug Patent Profile

When do Implanon patents expire, and what generic alternatives are available?

Implanon is a drug marketed by Organon and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-seven countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Implanon

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 16, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for IMPLANON

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	26
Patent Applications:	2,423
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMPLANON
DailyMed Link:	IMPLANON at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMPLANON

Constraining patent/regulatory exclusivity:

EXTENSION OF THE DURATION OF USE FROM 3 YEARS TO 5 YEARS

NDA:

021529

Dosage:

IMPLANT;IMPLANTATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMPLANON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mata Poli de Arajo	EARLY_PHASE1
Organon	EARLY_PHASE1
Eastern Virginia Medical School	Phase 4

See all IMPLANON clinical trials

Pharmacology for IMPLANON

Drug Class

Progestin

US Patents and Regulatory Information for IMPLANON

IMPLANON is protected by one US patents.

This potential generic entry date is based on EXTENSION OF THE DURATION OF USE FROM 3 YEARS TO 5 YEARS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006		DISCN	No	No			Y

Expired US Patents for IMPLANON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006
Organon	IMPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-001	Jul 17, 2006

International Patents for IMPLANON

When does loss-of-exclusivity occur for IMPLANON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Egypt

Latvia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMPLANON around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	86484
Australia	2044988
Australia	603475
Canada	1309949	IMPLANT CONTRACEPTIF (CONTRACEPTIVE IMPLANT)
China	1024753
China	1031323
Germany	19975054

Supplementary Protection Certificates for IMPLANON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303306	SPC/GB99/044	United Kingdom		PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
0303306	C980027	Netherlands		PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
0303306	099C0041	Belgium		PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306	29/1999	Austria		PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825

Last updated: June 9, 2026

IMPLANON market dynamics and financial trajectory: demand, pricing, competition, and exclusivity risk

Executive summary: IMPLANON (etonogestrel implant) is a long-established, globally distributed contraceptive with a product life cycle dominated by demand stability, regulatory switching between legacy implant SKUs and newer implant systems, and pricing pressure from national formulary decisions and competing long-acting reversible contraceptives (LARC). Financial outcomes track tightly to (1) government procurement and tender cycles, (2) reimbursed patient access in key markets, and (3) conversion from older implant products to next-generation/alternate brands where regulators and payers favor updated supply contracts. Patent risk is generally lower than for oncology and specialty drugs because the active ingredient class is off-patent in most jurisdictions; the main remaining IP and market risk typically comes from formulation and delivery-system patents, country-specific secondary patents, and market-entry dynamics for generics or authorized copies rather than classic blockbuster-style exclusivity cliffs.

---

How big is the IMPLANON market and what drives demand by geography?

Answer (featured snippet): IMPLANON demand is driven by public-sector and private payer coverage of LARC, clinician prescribing patterns, and national procurement/tender schedules for contraceptives; sales tend to be resilient but capped by population-level adoption rates and substitution by competing implants and IUDs.

What categories of customers buy IMPLANON

IMPLANON is primarily sold into:

• Public procurement channels where ministries of health run tenders for contraceptive implant programs.
• Hospital and clinic formularies where stocking decisions hinge on reimbursement and device training.
• Private payer markets where patient out-of-pocket dynamics affect uptake.

Which countries typically determine the financial trajectory

Financial trajectory is usually set by a handful of high-volume geographies where implant contraception is either:

• systematically funded (tender-based supply and distribution), or
• actively incentivized through reproductive health programs.

In many markets, the commercial story is less about “brand switching” among multiple implant brands and more about whether implant contraception is expanding as a category versus losing share to competing LARC such as levonorgestrel-releasing IUDs.

What demand indicators matter most

For implant products like IMPLANON, the leading indicators behind sales growth or decline are:

• Share of LARC in contraceptive mix (implant uptake vs IUD vs pills/condoms)
• Adoption by provider networks (training and insertion capacity)
• Reimbursement status (coverage breadth, patient copays)
• Supply continuity (stock availability in tender-funded programs)

---

Why do IMPLANON sales fluctuate: tender cycles, procurement, and supply availability

Answer (featured snippet): Sales volatility for IMPLANON is usually procurement-driven, with quarterly outcomes tied to tender awards, stocking lead times, and clinic-level training capacity.

Tender and procurement mechanics

When contraceptives are procured through government tenders, commercial performance depends on:

• award timing and contract length,
• delivery schedules that can shift volumes between periods,
• product availability and fulfillment performance under supply agreements.

Supply continuity and working capital effects

Implant products face:

• forecast sensitivity (small errors can cause stockouts),
• batch release and distribution constraints, and
• training requirements that delay utilization even when units are in-country.

These dynamics can create a pattern where revenue and shipments move out of sync with “true demand.”

Price and reimbursement shocks

Pricing pressure typically comes from:

• next tender pricing benchmarks set by competitors,
• national formulary restrictions or preferential contracting,
• payer reimbursement revisions that shift patient access.

---

How has the competitive landscape affected IMPLANON’s growth or decline?

Answer (featured snippet): IMPLANON competes in the LARC category, mainly against IUDs and alternative implants; competition tends to be substitution at the payer and provider level rather than high-volume head-to-head brand switching driven by differentiating pharmacology.

Main competitive threats

1. Alternative etonogestrel implant offerings (authorized copies and next-generation product presentations where available)
2. Levonorgestrel-releasing IUDs (strong incumbency in many markets)
3. Non-implant LARC with broader payer uptake in certain health systems

Why IUDs often win share

IUD adoption can increase when programs emphasize:

• long duration without frequent patient follow-up,
• clinician familiarity and insertion networks,
• bundled reproductive health services.

Implants can still hold strong positions, but financial upside is often limited by IUD category expansion.

---

Does IMPLANON face generic entry risk and how would it affect revenue?

Answer (featured snippet): Generic and authorized-copy risk is primarily a market access issue in specific jurisdictions; revenue impact depends on whether new entrants secure formulary status or tender awards rather than only on legal patent expiration.

What matters legally in off-patent generics

Because etonogestrel implants are older, the economic threat typically is:

• country-specific residual IP that blocks certain device components or insertion systems,
• procedural barriers (regulatory approval requirements),
• market uptake friction (provider training and clinician preference).

Market-entry scenarios that change the revenue curve

1. Formulary inclusion without tender replacement: modest price pressure, slower share shift.
2. Tender displacement: larger shipment-based revenue step-down at the contract level.
3. Selective regional entry: geographically constrained impact with uneven financial results.

What to watch in indicators

• sudden declines in procurement allocations in major tenders,
• rapid uptake by clinic networks after device training campaigns,
• widened discounting and channel stocking changes.

---

What is the Orange Book status of IMPLANON and does exclusivity still matter?

Answer (featured snippet): IMPLANON’s Orange Book exclusivity implications are typically limited for a legacy contraceptive product because the active ingredient is long established; current market dynamics are usually driven by market access and competition more than by new regulatory exclusivity cliffs.

How exclusivity usually shows up for contraceptives

For legacy products, FDA incentives or exclusivity are commonly not the dominant determinant unless:

• a new NDA or supplement created a fresh exclusivity period, or
• there were device-related or formulation changes tied to exclusivity.

For business modeling, exclusivity is less about “new entry blocked” and more about whether regulators maintain specific product listings and how quickly copies can be substituted through approvals.

---

What patents protect IMPLANON and where are the residual IP barriers?

Answer (featured snippet): Residual patent protection, where it exists, typically centers on delivery system design, applicator and insertion components, and certain formulation or manufacturing features rather than the core hormone molecule.

Residual IP categories that affect market access

• Device and delivery system claims: applicator design, insertion mechanics, implant geometry and release features.
• Manufacturing and process claims: sterilization, implant preparation, and quality control processes.
• Formulation and stability claims: excipients, implant matrix characteristics, and coating or dispersion mechanisms.

How that translates to commercial risk

Even if the active ingredient is off-patent, device-claim enforcement or licensing can:

• delay or restrict approvals,
• raise the cost of entry for would-be competitors,
• reduce the speed of tender displacement.

---

How does IMPLANON compare with competing LARC products on market access and economics?

Answer (featured snippet): Economic performance for IMPLANON is best modeled as category share plus tender access rather than as unique clinical superiority; competitors that align better with payer procurement preferences can outpace it even with similar clinical outcomes.

Key comparison axes

• Duration of action and follow-up model (affects clinic workflow)
• Tender pricing (drives contract wins)
• Patient acceptance and adverse-event management (affects continuation and switching)
• Availability and supply continuity (drives realized utilization)

Where IMPLANON tends to hold advantages

• entrenched provider familiarity in geographies where it has long been stocked,
• stable LARC programs that maintain implant procurement,
• clinician routines for insertion and removal.

---

What regulatory and supply-chain factors shape IMPLANON’s financial trajectory?

Answer (featured snippet): Supply-chain reliability, regulatory maintenance, and batch release timelines are recurring determinants of shipment realization and therefore revenue recognition.

Regulatory maintenance

Implant contraceptives require:

• consistent manufacturing quality,
• ongoing product monitoring,
• periodic updates to keep listings current.

When regulatory or quality issues arise, they often show up commercially as missed shipments rather than as pricing pressure.

Supply-chain constraints

Implants require specialized handling and trained insertion/removal workflows. Even if product exists, commercial performance can lag due to:

• delayed distribution into clinics,
• training bottlenecks after tender awards.

---

IMPLANON revenue outlook: what drives near-term growth versus decline?

Answer (featured snippet): Near-term financial trajectory is primarily determined by (1) tender award outcomes in high-volume markets, (2) category growth in LARC penetration, and (3) competitive substitution by IUDs and alternate implants.

Growth drivers

• increased LARC adoption programs (implant-focused contraception initiatives),
• expanded reimbursement or reduced patient access barriers,
• improved supply continuity that converts contracted volumes into shipped volumes.

Downside drivers

• tender displacement by alternative implants or IUDs,
• pricing pressure that compresses contract margins,
• supply interruptions that reduce realized utilization.

Base-case dynamics for modeling

In mature contraceptive markets, a realistic model treats revenue as:

• relatively stable within each procurement cycle,
• prone to step-change effects upon contract award shifts.

---

Key Takeaways

• IMPLANON’s market and financial trajectory is procurement- and reimbursement-driven, with outcomes shaped by tender cycles and provider utilization capacity.
• Competitive risk is mainly substitution within LARC, especially IUD adoption and alternative implant offerings, not classic blockbuster-style exclusivity cliffs.
• Generic or authorized-copy impact tends to be realized through formulary and tender displacement, not merely legal expiration.
• Residual IP, where relevant, usually targets device delivery system and manufacturing features, influencing entry speed and adoption friction.
• Near-term revenue direction should be modeled around category adoption (LARC penetration) and country-specific contract outcomes.

---

FAQs

1. When do implant contraceptive tender contracts typically create quarterly revenue swings for legacy products like IMPLANON?
   Tender awards, deliveries, and clinic stocking lead to step changes across quarters, often independent of underlying demand.

2. How does LARC penetration rate affect IMPLANON growth more than pricing changes?
   Category expansion typically lifts demand ceiling; pricing changes mainly determine share within a fixed or slowly changing category.

3. What substitution patterns are most common: IMPLANON vs IUDs vs alternate implants?
   Substitution often flows to the LARC option favored by payer procurement and clinician workflows, frequently IUDs in systems emphasizing long-duration single-device coverage.

4. Do device-related patents or applicator designs matter for market entry of etonogestrel implant competitors?
   Yes; even when the hormone is off-patent, delivery system and manufacturing constraints can slow approvals and raise entry costs.

5. What operational factors most often reduce realized sales for implant products even when demand exists?
   Supply continuity issues, clinic-level training constraints, and distribution timing after tender awards.

---

References

No sources were provided in the prompt.